Intra-Cellular Therapies to Present at the 55th Annual Meeting of the American College of Neuropsychopharmacology
December 01 2016 - 8:00AM
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical
company focused on the development of therapeutics for central
nervous system (CNS) disorders, today announced two ITI-007 poster
presentations at the 55th Annual Meeting of the American
College of Neuropsychopharmacology being held
in Hollywood, Florida, December 4-8, 2016.
The poster presentation (Abstract M180), titled "Advancing the
Clinical Development of Lumateperone (ITI-007) for the Treatment of
Schizophrenia – Efficacy Data," will take place on Monday, December
5, 2016, 5:30 pm – 7:30 pm ET during Poster Session
I.
The poster presentation (Abstract M173), titled "Advancing the
Clinical Development of Lumateperone (ITI-007) for the Treatment of
Schizophrenia – Safety and Tolerability Data," will also take place
on Monday, December 5, 2016, 5:30 pm – 7:30 pm
ET during Poster Session I.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the
treatment of neuropsychiatric and neurodegenerative diseases and
diseases of the elderly, including Parkinson's and Alzheimer's
disease. The Company is developing its lead drug candidate,
ITI-007, for the treatment of schizophrenia, bipolar disorder,
behavioral disturbances in patients with dementia, including
Alzheimer's disease, depression and other neuropsychiatric and
neurological disorders. ITI-007, a first-in-class molecule, is in
Phase 3 clinical development for the treatment of schizophrenia,
bipolar depression and agitation associated with dementia,
including Alzheimer's disease. The Company is also utilizing its
phosphodiesterase platform and other proprietary chemistry
platforms to develop drugs for the treatment of CNS and other
disorders.
Contact:
Juan Sanchez, M.D.
Vice President
Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc.
Phone: 212-923-3344
Burns McClellan, Inc.
Lisa Burns
Justin Jackson (Media)
Email: jjackson@burnsmc.com
Phone: 212-213-0006
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Apr 2023 to Apr 2024